A phase 2b, randomised, double-blind, placebo-controlled, multi-site, parallel-group, dose finding trial to evaluate the efficacy and safety of different doses of subcutaneously administered LEO 138559 in adult subjects with moderate-to-severe atopic dermatitis (AD)

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500777-14-00

Acronym

LP0145-2240

Enrollment

153

Registered

2023-10-11

Start date

2023-11-06

Completion date

2025-04-03

Last updated

2025-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

Percent change in EASI score from baseline to Week 16

Detailed description

Number of TEAEs recorded for each subject from baseline to Week 16.

Interventions

DRUGLEO138559 solution for injection (150 mg/ml)

DRUGPlacebo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Percent change in EASI score from baseline to Week 16	—

Secondary

Measure	Time frame
Number of TEAEs recorded for each subject from baseline to Week 16.	—

Countries

Czechia, France, Germany, Hungary, Poland, Romania, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026